SITC 2023 | PERIO: novel SD-101 treatment of uveal melanoma

Diwakar Davar, MD, University of Pittsburgh School of Medicine, Pittsburgh, PA, provides an overview of the PERIO trial (NCT04935229), utilizing an novel treatment for liver tumors whereby the TLR9 agonist SD-101 is administered to the liver via catheter. This novel delivery method overcomes the liver pressures that normally prevent the effective delivery of drugs, whilst SD-101 overcomes the immune resistance in the liver. High proportions of liver metastasis and the extraordinarily immunosuppressive liver environment are current unmet needs in uveal melanoma, and the efficacy of this trial appears to address this; when administered alongside immunotherapy SD-101 treatment via catheter is safe, produces sustained effects and does not escape the liver. Reductions in patients’ circulating tumor DNA (ctDNA) suggests the desired effects are in force. This interview took place at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.